| Status | In progress |
| Technology type | Medicine |
| Decision | Selected |
| Process | STA Standard |
| ID number | 1333 |
Provisional Schedule
| Committee meeting | 06 November 2024 |
| Expected publication | 29 January 2025 |
Project Team
| Project lead | Celia Mayers |
Email enquiries
- If you have any queries please email TATeam6@nice.org.uk
Stakeholders
| Companies sponsors | Johnson and Johnson Innovative Medicine |
| Others | Department of Health and Social Care |
| HS England | |
| Patient carer groups | Action Bladder Cancer UK |
| Black Health Agency for Equality | |
| Bladder and Bowel Community | |
| Bladder and Bowel UK | |
| Cancer 52 | |
| Cancer Black Care | |
| Cancer Equality | |
| Fight Bladder Cancer | |
| Helen Rollason Cancer Charity | |
| Independent Cancer Patients Voice | |
| Macmillan Cancer Support | |
| Maggie’s Centres | |
| Marie Curie | |
| Pelican Cancer Foundation | |
| South Asian Health Foundation | |
| Specialised Healthcare Alliance | |
| Tenovus Cancer Care | |
| Professional groups | Association of Cancer Physicians |
| British Association of Urological Nurses | |
| British Association of Urological Surgeons | |
| British Geriatrics Society | |
| British Gynaecological Cancer Society | |
| British Institute of Radiology | |
| British Oncology Pharmacy Association | |
| British Psychosocial Oncology Society | |
| British Society of Urogenital Radiology | |
| British Society of Urogynaecology | |
| British Uro-Oncology Group | |
| Cancer Research UK | |
| Royal College of General Practitioners | |
| Royal College of Nursing | |
| Royal College of Pathologists | |
| Royal College of Physicians | |
| Royal College of Radiologists | |
| Royal Pharmaceutical Society | |
| Royal Society of Medicine | |
| Society and College of Radiographers | |
| UK Clinical Pharmacy Association | |
| UK Oncology Nursing Society | |
| Urology Foundation | |
| Associated public health groups | Public Health Wales |
| UK Health Security Agency | |
| Comparator companies | Bristol Myers Squibb Pharmaceuticals limited (nivolumab) |
| Celgene (paclitaxel) | |
| Hospira UK Ltd (docetaxel, paclitaxel) | |
| Merck, Sharp & Dohme (pembrolizumab) | |
| Roche (atezolizumab) | |
| Seacross Pharmaceuticals (docetaxel, | |
| paclitaxel) | |
| Teva UK Limited (paclitaxel | |
| General commentators | All Wales Therapeutics and Toxicology Centre |
| Allied Health Professionals Federation | |
| Board of Community Health Councils in Wales | |
| British National Formulary | |
| Care Quality Commission | |
| Department of Health, Social Services and Public Safety for Northern Ireland | |
| Healthcare Improvement Scotland | |
| Medicines and Healthcare products Regulatory Agency | |
| National Association of Primary Care | |
| National Pharmacy Association | |
| NHS Confederation | |
| Scottish Medicines Consortium | |
| Welsh Government | |
| Welsh Health Specialised Services Committee | |
| Relevant research groups | Cochrane UK |
| Cochrane Urology | |
| Genomics England | |
| Institute of Cancer Research | |
| MRC Clinical Trials Unit | |
| National Institute for Health Research |
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 22 April 2024 | Invitation to participate |
| 16 January 2024 - 13 February 2024 | Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: ID1333 |
| 16 January 2024 | In progress. Scoping commenced. |
| 23 October 2023 | Please note that following on from advice received from the company this appraisal has been rescheduled to align with latest regulatory expectations. Therefore, we now anticipate that the appraisal will begin during mid-April 2024 when we will write to you about how you can get involved. The deadline for submissions is expected in approximately mid-June 2024. |
| 13 December 2018 | Following notification from the company, the timelines for this appraisal will be confirmed once regulatory approval timelines have been established. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties as and when the situation changes. |
| 03 September 2018 | This appraisal will be rescheduled to allow the company to include important data to be presented in their submission. This delay means that this appraisal will be removed from the NICE’s reporting targets for timeliness. In addition, through this request for delay the company accepts that this drug will not be eligible to receive interim CDF funding from the date of marketing authorisation. |
| 06 June 2018 | The Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of erdafitinib for treating metastatic or unresectable FGFR-positive urothelial cancer. Following on from an update from the company, the timelines for this appraisal remain to be confirmed. As this appraisal has been referred to NICE we will continue to monitor any development and will update interested parties as and when the situation changes. |
| 28 September 2017 | In progress. In progress |
For further information on our processes and methods, please see our CHTE processes and methods manual